A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

A Clamp; M Adams; R Atkinson; E. Boven; AH Calvert; A Cervantes; T Ganesan; J Lotz; P Vasey; P Cheverton; GC Jayson

doi:10.1016/j.ygyno.2004.06.047

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

A Clamp, M Adams, R Atkinson, E. Boven, AH Calvert, A Cervantes, T Ganesan, J Lotz, P Vasey, P Cheverton, GC Jayson

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	114-9
Journal	Gynecologic Oncology
Volume	95
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2004.06.047
Publication status	Published - 2004

Access to Document

10.1016/j.ygyno.2004.06.047

Embargoed Document

170530
Final published version, 113 KB

Cite this

Clamp, A., Adams, M., Atkinson, R., Boven, E., Calvert, AH., Cervantes, A., Ganesan, T., Lotz, J., Vasey, P., Cheverton, P., & Jayson, GC. (2004). A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecologic Oncology, 95(1), 114-9. https://doi.org/10.1016/j.ygyno.2004.06.047

@article{38f7495741634f5089d5519380c9cfa9,

title = "A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.",

author = "A Clamp and M Adams and R Atkinson and E. Boven and AH Calvert and A Cervantes and T Ganesan and J Lotz and P Vasey and P Cheverton and GC Jayson",

year = "2004",

doi = "10.1016/j.ygyno.2004.06.047",

language = "English",

volume = "95",

pages = "114--9",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

Clamp, A, Adams, M, Atkinson, R, Boven, E, Calvert, AH, Cervantes, A, Ganesan, T, Lotz, J, Vasey, P, Cheverton, P & Jayson, GC 2004, 'A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.', Gynecologic Oncology, vol. 95, no. 1, pp. 114-9. https://doi.org/10.1016/j.ygyno.2004.06.047

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. / Clamp, A; Adams, M; Atkinson, R et al.

In: Gynecologic Oncology, Vol. 95, No. 1, 2004, p. 114-9.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

AU - Clamp, A

AU - Adams, M

AU - Atkinson, R

AU - Boven, E.

AU - Calvert, AH

AU - Cervantes, A

AU - Ganesan, T

AU - Lotz, J

AU - Vasey, P

AU - Cheverton, P

AU - Jayson, GC

PY - 2004

Y1 - 2004

U2 - 10.1016/j.ygyno.2004.06.047

DO - 10.1016/j.ygyno.2004.06.047

M3 - Article

SN - 0090-8258

VL - 95

SP - 114

EP - 119

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 1

ER -